# A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

> **NCT06798207** · PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 170 (estimated)

## Conditions studied

- Gynecological Tumors

## Interventions

- **DRUG:** TQB2102 for injection

## Key facts

- **NCT ID:** NCT06798207
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-13
- **Primary completion:** 2026-05
- **Final completion:** 2026-11
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06798207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06798207, "A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06798207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*